Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Effect Of Fingolimod On Disease Progressions, Relapse Rate And Brain Atrophy In Multiple Sclerosis Patients: Review Of Literature And Pharmacoeconomic Considerations.
Long-distance effects of inflammation on differentiation of adult spinal cord neural stem/progenitor cells.
Advances in myelin imaging with potential clinical application to pediatric imaging.
Assessing tissue damage in multiple sclerosis: a biomarker approach.
HHV-6-positivity in diseases with demyelination.
αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features.
Design, Synthesis, and Evaluation of Fluorinated Radioligands for Myelin Imaging.
Commentary: Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis.
Immunoregulatory Effects of Interferon-β in Suppression of Th17 cells.
The Effect of Neural Lesion Type on Botulinum Toxin Dosage: A Retrospective Chart Review.
Frequency distribution of the first clinical symptoms in the Iranian population with multiple sclerosis.
Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.
Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing.
Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection.
Sequence of Molecular Events during the Maturation of the Developing Mouse Prefrontal Cortex.
MyelStones: the executive roles of myelin basic protein in myelin assembly and destabilization in multiple sclerosis.
Gut commensalism, cytokines, and central nervous system demyelination.
Why are prions and amyloid structures immune suppressive and other intriguing questions facing neuroimmunologists in the future.
Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada.
Antibody Recognition In Multiple Sclerosis And Rett Syndrome Using A Collection Of Linear And Cyclic N-glucosylated antigenic probes.
More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Multiple sclerosis - New treatment modalities.
Highlights from this issue.
Correction: Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
Pages
« first
‹ previous
…
668
669
670
671
672
673
674
675
676
…
next ›
last »